FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...
The following is a summary of “Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A ...
MyChesCo on MSN3d
Pioneering Discovery by The Wistar Institute Offers New Hope in Ovarian Cancer TreatmentPHILADELPHIA, PA — The Wistar Institute has unveiled a groundbreaking approach to tackling ovarian cancer, potentially ...
The Wistar Institute's Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center's Molecular and ...
Medpage Today on MSN11d
Adding HIPEC Boosts Survival in Recurrent Ovarian CancerThe 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
Zacks.com on MSN6d
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in EuropeThe EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...
fallopian tube or primary peritoneal cancers. The therapy is authorised for patients who have undergone one to three prior ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Wistar Institute Researchers Discover New Combination Therapy Approach for Metastatic Ovarian Cancer
“This is the first time researchers have been able to indirectly target ovarian cancer cells in peritoneal fluid by inducing ...
"This is the first time researchers have been able to indirectly target ovarian cancer cells in peritoneal fluid by inducing an immune reaction, in preclinical models," said Zhang. "We look forward to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback